



June 4, 2021

For Truli for Health and Florida Blue Providers

COVID-19 SPECIAL ALERTS

COVID-19 Update as of April 29, 2021

In response to the coronavirus disease (COVID-19), we have made additional process updates which are now in place for our Commercial, Affordable Care Act (ACA), Medicare Advantage, Federal Employee Program® (FEP) and Truli for Health lines of business. We will keep you informed as information changes. **Note: For easy reference, new updates are noted in red throughout the communication.** [Learn more>>](#)

COVID-19 Provider Billing Guidelines

To ensure proper, timely reimbursement, please submit claims using the provider billing guidelines in the link below. Please check these guidelines regularly as they will be updated as needed. [Click here](#) and select **COVID-19 Provider Billing Guidelines**.

ADMINISTRATIVE NEWS

Earn Free CEUs for Attending ABA Webinar

New Directions Behavioral Health will offer a series of free educational applied behavior analysis (ABA) webinars led by Board Certified Behavior Analysts. Providers who attend webinars can earn free CEUs. [Learn more>>](#)

We Are Switching Out Legacy Claim Status with Availity's All Payer Application

On June 19, 2021, Florida Blue's **Go to Legacy App** button will disappear from Availity®. To check the status of a claim, you will have one option, Availity's All Payer application. It will allow you to check any payer's claim status from one location. [Learn more>>](#)

COMPLIANCE

An Important Reminder About Rules for Retaining Medical Records

We want to remind providers and suppliers of state and federal requirements for maintaining medical records and other documents. This is important for all patient

records whether our members are in commercial plans, qualified health plans or Medicare Advantage plans. [Learn more>>](#)

For Florida Blue Providers Only

PHARMACY

Changes in Pharmacy Coverage Affect Select Drugs as of July 1, 2021

Starting July 1, 2021, Neulasta, Neulasta OnPro and Ziextenzo will be required before allowing coverage of other pegfilgrastim biosimilar products. Udenyca will no longer be a preferred option. Patients with existing authorizations for Udenyca can continue for the duration of their current authorization. This change only applies to our commercial members being newly initiated on treatment. [Learn more>>](#)

¹Availity LLC is a multi-payer joint venture company. To register or for more information, visit availity.com.

